
John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and clinically testing novel immunotherapeutics for the treatment of cancer. He is a co-founder of OV biotechs Jennerex and Turnstone Biologics. John is a senior scientist at the Ottawa Hospital Research Institute (OHRI), a research institution affiliated with the University of Ottawa and the research arm of The Ottawa Hospital. John launched his independent research career in the Department of Biochemistry at McGill University.
His research program has been continuously funded by peer-reviewed grants for over 30 years and he has authored over 400 publications.
He completed his post-doctoral studies at the Medical Research Council in London, England and received his PhD in virology and immunology at McMaster University in Ontario, Canada.

Antoine Italiano , MD, PhD, is a renowned medical oncologist specializing in early drug development and precision medicine. He serves as Head of the Department of Medicine at Institut Bergonié in Bordeaux and leads the Precision Medicine program at Gustave Roussy in Paris. Prof. Italiano has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III trials in the past five years. His research focuses on immuno-oncology, targeted therapies, and translational research, particularly in rare tumors like sarcomas.
He earned his PhD in Molecular Cell Biology in 2008 and completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in New York.
Prof. Italiano is a member of ASCO, AACR, and ESMO, and regularly reviews for top oncology journals. He has authored or co-authored over 500 peer-reviewed publications, including in Nature Medicine, Lancet Oncology, and JAMA Oncology.
He coordinates the CONDOR project, which combines precision medicine and immunotherapy to improve outcomes for metastatic sarcoma patients. Prof. Italiano is also involved in the Multipli study, part of France’s Genomic Medicine 2025 plan, aiming to expand genomic testing in cancer care.
His work has significantly shaped the field of precision oncology, bridging clinical gaps and driving therapeutic innovation.

Ignacio Melero , MD, PhD, is a full professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra. He is widely recognized for his pioneering work in cancer immunotherapy, particularly on immunostimulatory monoclonal antibodies and co-stimulation of antitumor immune responses.
He spent three years conducting research at Bristol-Myers Squibb in Seattle, collaborating with leading scientists such as Lieping Chen and Karl Hellström. Since returning to Spain in 1998, he has led a multidisciplinary team at CIMA and the Clínica Universidad de Navarra, focusing on cell-based immunotherapy, gene therapy, and monoclonal antibodies. Prof. Melero has served as principal investigator in over 40 clinical trials in immunotherapy, sponsored by both pharmaceutical companies and academic institutions.
He is a scientific editor for several prestigious journals, including Clinical Cancer Research, Cancer Discovery, and Journal for Immunotherapy of Cancer. He sits on multiple international scientific advisory boards, including those of Institut Curie (Paris), Gustave Roussy, the Netherlands Cancer Institute (NKI), and the Biomedical Research Institute of Granada. In 2023, he was appointed Kidani Professor of Cancer Immuno-Therapeutics at the University of Oxford.
He has published more than 350 scientific articles and supervised over 16 PhD theses, many of which have received awards for excellence. In 2024, he was awarded a prestigious ERC Advanced Grant from the European Union for his research on mRNA-based immunotherapies.

Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer.
Previously, Pedro researched at the Department of Medical and Molecular Parasitology at New York University School of Medicine before joining the Ludwig Institute for Cancer Research (LICR), Epalinges, Switzerland, in 1989. In 2001, he became division Head of Clinical Onco-Immunology at the LICR in Lausanne.
Pedro holds a number of patents and has coauthored more than 320 original research articles describing his scientific works in peptide-based immunotherapy and T cell responses.
Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.
Last update : March 2026.